Kelowna, British Columbia – TheNewswire - August 14, 2025 – Lexaria Bioscience Corp. (Nasdaq: LEXX, LEXXW) (the “ Company ” or “ Lexaria ”), a global innovator in drug delivery platforms, is pleased to announce that its Contract Research Organization (“ CRO ”) has completed the important study milestone known as last patent last visit (“ LPLV ”) in Lexaria's Phase 1b glucagon-like peptide-1 (“ GLP-1 ”) study in Australia, GLP-1-H24-4 (the “ Study ”). “We are delighted that this important milestone has been achieved on schedule, concluding all patient dosing and clinical testing in our Study,” said John Docherty, …

KELOWNA, BC / ACCESS Newswire / August 14, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce that its Contract Research Organization ("CRO") has completed the important study milestone known as last patent last visit ("LPLV") in Lexaria's Phase 1b glucagon-like peptide-1 ("GLP-1") study in Australia, GLP-1-H24-4 (the "Study"). "We are delighted that this important milestone has been achieved on schedule, concluding all patient dosing and clinical testing in our Study," said John Docherty, Lexaria's President and CSO.

BigBear.ai Holdings, Inc.'s Q2 '25 results show declining revenue, shrinking margins, and ballooning losses, despite management's optimism and strong cash reserves. The current $5.81 share price reflects speculation, not fundamentals; the stock's 350% rally lacks support from real business progress or profitability. For an upgrade, I need to see reduced cash burn, meaningful new contracts, and tangible revenue from international partnerships in Q3.

AUSTIN, Texas , Aug. 14, 2025 /PRNewswire/ -- Ideal Power Inc. (Nasdaq: IPWR) ("Ideal Power," the "Company," "we," "us" or "our"), developer and innovative provider of the highly efficient and broadly patented B-TRAN® bidirectional semiconductor power switch, reports results for its second quarter ended June 30, 2025. "Our first design win customer is nearing completion of their B-TRAN®-enabled solid-state circuit breaker (SSCB) prototype testing.

Brinker International Inc. NYSE: EAT stock is surging over 2.5% on strong volume after the company's strong second-quarter earnings report. The company reported strong, 21.3% same-store sales growth for its Chili's and Maggiano's chains.

LOS ANGELES , Aug. 14, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against SelectQuote, Inc. ("SelectQuote" or "the Company") (NYSE: SLQT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between September 9, 2020 and May 1, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before October 10, 2025.

ON Semiconductor Corporation faces persistent margin pressure and underwhelming results despite recent sector-driven volatility and rallies. Q2 earnings results and guidance were largely in line with low expectations, with no meaningful near-term automotive rebound expected. Valuation has deteriorated significantly, with 2027 targets now appearing unachievable and fair value estimates dropping to the mid-$50s.

Cellebrite DI Ltd. (CLBT) came out with quarterly earnings of $0.12 per share, beating the Zacks Consensus Estimate of $0.1 per share.

Canaan (CAN) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.15 per share a year ago.

The most oversold stocks in the materials sector presents an opportunity to buy into undervalued companies.

Sunrun has further growth potential, according to Wells Fargo. Analyst Michael Blum reaffirmed his overweight rating on the residential solar panel manufacturer and lifted his price target by $6 to $14.

Welcome to the Green Stock News brief for Thursday August 14th. Here are today's top headlines: Surf Air Mobility (NYSE: SRFM) participated in Electra's first demonstration flights of its EL2 Ultra Short aircraft at Virginia Tech, which achieved takeoffs and landings in under 150 feet and showcased its ability to operate from unconventional locations.

Ford Motor Co. (NYSE: F) CEO Jim Farley said plans to build a new manufacturing system to produce its next-generation electric vehicle (EV) present a risk.

LAS VEGAS, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Jet.AI Inc. ( “Jet.AI” or the “Company”) (Nasdaq: JTAI), a provider of high-performance GPU infrastructure and AI cloud services, today announced it has made a capital contribution to AIIA Sponsor Ltd. (“Sponsor”) which serves as the sponsor of AI Infrastructure Acquisition Corp., a special purpose acquisition company. On August 13, 2025, AI Infrastructure Acquisition Corp. filed a Registration Statement on Form S-1 (the "Registration Statement") with the Securities and Exchange Commission ("SEC") in connection with a proposed initial public offering of its units.

SOUTH SAN FRANCISCO, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it will present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech being held virtually August 19-21, 2025.

MIAMI, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Wrap Technologies, Inc. (NASDAQ: WRAP) (the “Company” or “Wrap”), a global leader in innovative public safety technology, today announced its second research and development counter-unmanned aircraft systems (C-UAS) initiative and released a Phase One video showing proof of concept on its website (www.Wrap.com). Wrap's Project PAN-DA (Personal Anti-Drone Armament) concept is a handheld counter-drone system derived from the Company's proven BolaWrap® 150 platform.

- Live video webcast on Tuesday, August 19th at 2:40 PM ET HOUSTON, TX / ACCESS Newswire / August 14, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that it will present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech being held virtually August 19-21, 2025 Details for the presentation are as follows: Date and Time: Tuesday, August 19, 2025 at 2:40 PM ET Presenter: John Climaco, Chief Executive Officer Registration Link: HERE …

BOSTON and LONDON, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biotechnology company developing novel Antibody Drug Conjugates (ADCs) with immuno-oncology payloads for the treatment of cancer, today announced that it will present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech being held virtually August 19-21, 2025. Details for the presentation are as follows: Date and Time: Tuesday, August 19, 2025 at 2:00 PM ET Presenter: Abizer Gaslightwala, President and Chief Executive Officer of Akari Registration Link: HERE About Webull Financial Webull Financial is a leading online brokerage platform committed to empowering self-directed investors with …

– Live video webcast on Wednesday, August 20 th at 2:00 PM ET HOUSTON, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced that it will present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech being held virtually August 19-21, 2025. Details of the presentation are as follows: Date and Time: Wednesday, August 20, 2025 at 2:00 PM ET Presenter: Walter Klemp, Founder, President, CEO and Chairman of Moleculin Registration Link: HERE About Webull Financial …

Boca Raton, Florida--(Newsfile Corp. - August 14, 2025) - Entero Therapeutics, Inc. (NASDAQ: ENTO) (the "Company"), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced that, it will effect a 1 for 3 reverse stock split of its common stock. The Company expects its common stock to begin trading on a split-adjusted basis on the Nasdaq Capital Market as of the commencement of trading on August 18, 2025.